AstraZeneca equity cut not influenced by Boots

UK – The recent asset allocation shift that saw the £4.2bn (€6.8bn) AstraZeneca pension fund reduce its equity holdings by five percent in favour of fixed income was not influenced by the Boots pension fund getting rid of its entire equity portfolios last October.

“The decision was taken before Boots announced their move,” says Nicki Mortimer, director of AstraZeneca’s UK pension fund. She adds that the trustees took the decision purely in line with market conditions and that it was more a question of fund maturity than radical overhaul of its asset allocation policy.

Mortimer confirms that the split is now 45% fixed income, 55% equities. Furthermore, the percentage change is considered to be small enough as not to upset the way the fund is run. “The change is pretty small and we won’t need to change asset managers or do anything drastic to adjust to the revised portfolio split,” she comments.

Have your say

You must sign in to make a comment


Your first step in manager selection...

IPE Quest is a manager search facility that connects institutional investors and asset managers.

  • QN-2496

    Asset class: Commodities.
    Asset region: World.
    Size: CHF 100 – 150 m.
    Closing date: 2018-12-12.

  • QN-2498

    Asset class: Fixed Income Investment Grade.
    Asset region: Global Developed Markets.
    Size: $50m.
    Closing date: 2019-01-07.

  • DS-2499

    Closing date: 2019-01-02.

Begin Your Search Here